YC W23
Pando Bioscience
Gen-AI Designed Enzymes for Pharmaceutical Innovation
About
Pando is an AI-driven synthetic biology company revolutionizing enzyme engineering for the pharmaceutical industry. Our ultra-high-throughput screening platform screens 1000-fold more enzymes 75% faster and 80% cheaper than traditional methods. This empowers our generative AI to efficiently optimize enzymes across multiple properties, delivering high-performing, tailored enzymes that reduce costs and enhance efficiency.
Founder
Family Office Investors
Altss tracks family office allocations to YC-backed companies. Request access to see which family offices have invested in Pando Bioscience.
See family office activityIndustry & Focus
HealthcareIndustrial BioGenerative AISynthetic BiologyBiotechDiagnostics